Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Graft vs Host Disease 3Bronchiolitis Obliterans Syndrome 3Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Recurrence 1Anemia 1

Interventions

ibrutinib 3Imatinib Mesylate 2ruxolitinib 1nilotinib 1bosutinib 1belumosudil 1axatilimab 1Sirolimus 1Rituximab 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1Methotrexate 1KD025 1Infliximab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Bronchiolitis Obliterans Syndrome × ibrutinib × Clear all
NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Pharmacyclics LLC.

Phase 1/2 Completed
59 enrolled 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02195869 2019-07-11

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Pharmacyclics LLC.

Phase 1/2 Completed
45 enrolled 13 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡